BSX climbs around 3.5% after Q2 earnings beat and revenue surprise

Traders Union
All News
Stocks
Boston Scientific surges 3.51% today

Highlights

Boston Scientific reported second-quarter revenue of $5.44 billion, rising 7.5% year over year and exceeding forecasts.
Management lowered forward guidance despite an earnings per share surprise and announced $500 million in annual savings with seven new product launches targeted by 2028.
Shares gained 3.51% intraday, but technicals signal overbought conditions and project a short-term range of $46.9 to $51.94.

Guidance cut and investor exit temper strong earnings surprise

Boston Scientific reported second-quarter revenue of $5.44 billion, a 7.5% increase over the prior year and above analyst estimates. The company posted an earnings per share surprise of 3.61% above consensus. Management lowered future guidance, and Sapient Capital LLC revealed a significant reduction in its position, with plans for $500 million in annual savings and seven anticipated product launches by 2028 also announced.

Anton Kharitonov, expert at Traders Union, sees Boston Scientific’s recent rally as fragile. He notes that the earnings beat sparked short-term buying, but longer-term technicals remain bearish with the price well below the 200-day moving average. Management’s lowered guidance and a large shareholder reducing exposure are red flags for fundamental conviction. Momentum indicators are mixed and point to overbought conditions, limiting upside. "Persistent downward pressure and weak conviction make me skeptical about sustained gains at these levels," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, believes Boston Scientific offers attractive growth prospects. He highlights the solid 7.5% revenue increase and upbeat earnings performance. Product launches through 2028 and cost-saving plans suggest room for operational improvement. The bullish short- and medium-term trend signals further recovery potential. "I see the fundamental and structural setup as favorable for buyers seeking upside opportunity," Karapetjanc says.

Sholanke Dele, market strategist, questions the sustainability of the latest move in BSX. He notes that softer future guidance from management and Sapient Capital’s exit signal shaky confidence among insiders. Overbought technical signals suggest limited chasing from new buyers. "The current setup leaves me wary of downside risk outweighing the immediate upside," Dele says.

Mixed momentum as near-term bullishness clashes with stretched indicators

BSX trades above its 20-day ($45.1) and 50-day ($46.09) moving averages, which indicates bullish short- and medium-term momentum. However, it is still well below the 200-day ($72.44) moving average, pointing to a bearish longer-term trend. Immediate resistance is located at $49.49, while support stands at $49.03. The Ichimoku Kijun at $45.71 provides a more distant trend reference. Momentum signals are mixed: the MACD and RSI (currently 58.99, in the "Buy" zone) favor buyers, supported by a positive Awesome Oscillator and strong intraday Bull/Bear Power (BBP at 2.6). Contrasting this, the ADX, Stochastic RSI, CCI, and BBP flag overbought conditions and waning conviction. Intraday price action is mid-range, with volatility amplitude at 2.26%.

Earlier, analysts noted that Boston Scientific was experiencing persistent technical weakness, with price action and indicators signaling a sideways or hesitant trend. The latest earnings surprise, management updates, and continued mixed momentum add complexity to the picture, making the $49.49 resistance level pivotal for confirming a bullish breakout scenario going forward.

Source of Data: BSX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.